お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
968700

尿路感染症 (UTI) 治療市場 - 市場規模、シェア、見通し、機会分析:2020年~2027年

Urinary Tract Infection Treatment Market, By Drug Type, Quinolones, Cephalosporin, Azoles & Amphotericin B, & Other), Disease Indication, Distribution Channel, Region-Size, Share, Outlook, & Opportunity Analysis, 2020-2027

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 197 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.53円
尿路感染症 (UTI) 治療市場 - 市場規模、シェア、見通し、機会分析:2020年~2027年
出版日: 2020年09月14日
発行: Coherent Market Insights
ページ情報: 英文 197 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

尿路感染症 (UTI) は、細菌が尿道に侵入して膀胱に感染し、深刻な健康問題を引き起こします。UTI感染症は、男性よりも女性によく見られる健康上の問題で、生物学的要因が主な原因となっています。

当レポートでは、世界の尿路感染症 (UTI) 治療市場について調査分析し、市場概要、市場規模と予測、セグメント別の市場分析、地域別の市場分析、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 調査目的と前提条件

第2章 市場範囲

第3章 市場力学・規制・動向分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 影響分析
  • 主な発展
  • 規制シナリオ
  • PEST分析
  • COVID-19の影響分析

第4章 世界の尿路感染症 (UTI) 治療市場:薬剤の種類別

  • イントロダクション
  • ペニシリン・複合薬
  • キノロン
  • セファロスポリン
  • アミノグリコシド系抗生物質
  • スルホンアミド
  • アゾール・アムホテリシンB
  • テトラサイクリン
  • ニトロフラン
  • その他

第5章 世界の尿路感染症 (UTI) 治療市場:適応症別

  • イントロダクション
  • 複雑性UTI
  • 再発性複雑性UTI
  • 非複雑性UTI
  • 神経因性膀胱感染症

第6章 世界の尿路感染症 (UTI) 治療市場:流通チャネル別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 世界の尿路感染症 (UTI) 治療市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東
  • アフリカ

第8章 競合情勢

  • 企業プロファイル
    • Cipla Ltd.
    • Johnson & Johnson
    • Bayer AG
    • Pfizer Inc.
    • GlaxoSmithKline
    • Boehringer Ingelheim
    • F. Hoffmann-La Roche Ltd.
    • Iterum Therapeutics plc
    • Novartis AG
    • AstraZeneca Plc
    • Allecra Therapeutics
    • Shionogi Inc.
    • Spero Therapeutics, Inc.
    • Venatorx Pharmaceuticals.

第9章 セクション

目次

Title:
Urinary Tract Infection Treatment Market, By Drug Type (Penicillin & Combinations (Amoxicillin, "Amoxicillin+ Clavulanate, Potassium", Others)), Quinolones (Ciprofloxacin, Levofloxacin, Nalidixic acid, Norfloxacin, Others), Cephalosporin (Ceftriaxone, Cefuroxime, Cefixime, Cephalexin), Aminoglycoside Antibiotics (Amikacin, Gentamicin), "Sulphonamides (Sulfamethoxazole +, Trimethoprim)", Azoles and Amphotericin B, Tetracycline (Doxycycline), Nitrofurans (Nitrofurantoin), Other), By Disease Indication (Complicated UTI, Recurring Complicated UTI, Uncomplicated UTI, Neurogenic Bladder Infections), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Urinary Tract Infection (UTI) is caused when bacteria enters the urethra and infects the urinary bladder, causing severe health issues. UTI infections are common health problems in females than in males with biologic factors accounting as the major cause. Antibiotics are usually the first line of treatment prescribed by doctors for urinary tract infections. According to the site of manifestation by the microbe, infections are classified as cystitis (bladder), urethritis (urethra), prostatitis (prostate) or pyelonephritis (kidney). Painful and increased frequency of urination, excessive and involuntary passing of urine at night are the common symptoms associated with UTI. Hospitalized patients using urinary catheters are at a higher risk for developing UTI.

Restraints of the Global Urinary Tract Infection Treatment Market

Major factors hampering the growth of the urinary tract infection treatment market during the forecast period constitutes of low adoption of internet in some emerging economies.

Key features of the study:

  • This report provides in-depth analysis of the global urinary tract infection treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global urinary tract infection treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Iterum Therapeutics plc, Novartis AG AstraZeneca Plc, Allecra Therapeutics, Healthy.io, Shionogi Inc., Spero Therapeutics, Inc., and Venatorx Pharmaceuticals.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global urinary tract infection treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Urinary Tract Infection Treatment Market, By Drug Type:
    • Penicillin & Combinations
  • Amoxicillin
  • "Amoxicillin+ Clavulanate
  • Potassium"
  • Others
    • Quinolones
  • Ciprofloxacin
  • Levofloxacin
  • Nalidixic acid
  • Norfloxacin
  • Others
    • Cephalosporin
  • Ceftriaxone
  • Cefuroxime
  • Cefixime
  • Cephalexin
    • Aminoglycoside Antibiotics
  • Amikacin
  • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • Global Urinary Tract Infection Treatment Market, By Disease Indication:
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • Global Urinary Tract Infection Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Urinary Tract Infection Treatment Market, By Geography:
    • North America
  • By Drug Type
    • Penicillin & Combinations
      • Amoxicillin
      • "Amoxicillin+ Clavulanate
      • Potassium"
      • Others
    • Quinolones
      • Ciprofloxacin
      • Levofloxacin
      • Nalidixic acid
      • Norfloxacin
      • Others
    • Cephalosporin
      • Ceftriaxone
      • Cefuroxime
      • Cefixime
      • Cephalexin
    • Aminoglycoside Antibiotics
      • Amikacin
      • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • By Disease Indication
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • U.S.
    • Canada
    • Europe
  • By Drug Type
    • Penicillin & Combinations
      • Amoxicillin
      • "Amoxicillin+ Clavulanate
      • Potassium"
      • Others
    • Quinolones
      • Ciprofloxacin
      • Levofloxacin
      • Nalidixic acid
      • Norfloxacin
      • Others
    • Cephalosporin
      • Ceftriaxone
      • Cefuroxime
      • Cefixime
      • Cephalexin
    • Aminoglycoside Antibiotics
      • Amikacin
      • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • By Disease Indication
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • By Drug Type
    • Penicillin & Combinations
      • Amoxicillin
      • "Amoxicillin+ Clavulanate
      • Potassium"
      • Others
    • Quinolones
      • Ciprofloxacin
      • Levofloxacin
      • Nalidixic acid
      • Norfloxacin
      • Others
    • Cephalosporin
      • Ceftriaxone
      • Cefuroxime
      • Cefixime
      • Cephalexin
    • Aminoglycoside Antibiotics
      • Amikacin
      • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • By Disease Indication
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • By Drug Type
    • Penicillin & Combinations
      • Amoxicillin
      • "Amoxicillin+ Clavulanate
      • Potassium"
      • Others
    • Quinolones
      • Ciprofloxacin
      • Levofloxacin
      • Nalidixic acid
      • Norfloxacin
      • Others
    • Cephalosporin
      • Ceftriaxone
      • Cefuroxime
      • Cefixime
      • Cephalexin
    • Aminoglycoside Antibiotics
      • Amikacin
      • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • By Disease Indication
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East:
  • By Drug Type
    • Penicillin & Combinations
      • Amoxicillin
      • "Amoxicillin+ Clavulanate
      • Potassium"
      • Others
    • Quinolones
      • Ciprofloxacin
      • Levofloxacin
      • Nalidixic acid
      • Norfloxacin
      • Others
    • Cephalosporin
      • Ceftriaxone
      • Cefuroxime
      • Cefixime
      • Cephalexin
    • Aminoglycoside Antibiotics
      • Amikacin
      • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • By Disease Indication
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • By Drug Type
    • Penicillin & Combinations
      • Amoxicillin
      • "Amoxicillin+ Clavulanate
      • Potassium"
      • Others
    • Quinolones
      • Ciprofloxacin
      • Levofloxacin
      • Nalidixic acid
      • Norfloxacin
      • Others
    • Cephalosporin
      • Ceftriaxone
      • Cefuroxime
      • Cefixime
      • Cephalexin
    • Aminoglycoside Antibiotics
      • Amikacin
      • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other
  • By Disease Indication
    • Complicated UTI
    • Recurring Complicated UTI
    • Uncomplicated UTI
    • Neurogenic Bladder Infections
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Country/Region:
    • Central Africa
    • South Africa
    • North Africa
  • Company Profiles
    • Cipla Ltd.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
    • Johnson & Johnson
    • Bayer AG
    • Pfizer Inc.
    • GlaxoSmithKline
    • Boehringer Ingelheim
    • F. Hoffmann-La Roche Ltd.
    • Iterum Therapeutics plc
    • Novartis AG
    • AstraZeneca Plc
    • Allecra Therapeutics
    • Shionogi Inc.
    • Spero Therapeutics, Inc.
    • Venatorx Pharmaceuticals.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
  • Market Definition and Scope
    • Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Disease Indication
  • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis

4. Global Urinary Tract Infection Treatment Market, By Drug Type, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Penicillin & Combinations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Amoxicillin
    • Amoxicillin+ Clavulanate
    • Potassium"
    • Others
    • Quinolones
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Ciprofloxacin
    • Levofloxacin
    • Nalidixic acid
    • Norfloxacin
    • Others
    • Cephalosporin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Ceftriaxone
    • Cefuroxime
    • Cefixime
    • Cephalexin
    • Aminoglycoside Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Segment Trends
    • Amikacin
    • Gentamicin
    • "Sulphonamides (Sulfamethoxazole +
    • Trimethoprim)"
    • Azoles and Amphotericin B
    • Tetracycline (Doxycycline)
    • Nitrofurans (Nitrofurantoin)
    • Other

5. Global Urinary Tract Infection Treatment Market, By Disease Indication, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Complicated UTI
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Recurring Complicated UTI
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Uncomplicated UTI
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Neurogenic Bladder Infections
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Urinary Tract Infection Treatment Market, By Distribution Channel, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

7. Global Urinary Tract Infection Treatment Market, By Regions, 2019 - 2027 (US$ Mn)

    • Introduction
  • Market Share Analysis, 2019 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
    • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

    • Company Profiles
  • Cipla Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • F. Hoffmann-La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Iterum Therapeutics plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Allecra Therapeutics
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Shionogi Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Spero Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Venatorx Pharmaceuticals.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

    • References
    • Research Methodology
    • About us and Sales Contact
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.